Valneva surges after EU regulator validates Lyme disease vaccine application

Pfizer

14/08/2026 08:36

** French vaccine maker Valneva VLS.PA jumps 15.6% after the European Medicines Agency validated the marketing application for its Lyme disease vaccine candidate, developed with partner Pfizer PFE.N
** The validation marks a key regulatory milestone for the Lyme programme, which Kempen analysts describe as "the key" driver of the investment case
** The broker had flagged a potential filing by Pfizer during H2 2026 as a critical near-term catalyst, with a possible U.S. approval decision expected in H2 2027
** Kempen notes that Pfizer's latest commentary "continues to signal optimism on the vaccine candidate's prospects of approval"
** The shares are on track for their best day since August 2025 if the gains hold

(Reporting by Jerome Terroy)
((jerome.terroy@thomsonreuters.com))